IRVING, Texas, Jan. 5 /PRNewswire-FirstCall/ -- RBC Life Sciences announced today that it has elected current president, John W. Price, to CEO effective January 1, 2009. Company founder, Clinton Howard, who is currently CEO, will remain as chairman of the board of directors.
The promotion comes at a time when RBC Life Sciences, a global provider of proprietary nutritional supplements, wound care and pain management products, is growing domestically and internationally. The company announced recently that third quarter net sales and earnings both increased 26 percent over the same period last year.
“John possesses the perfect skill set to take RBC Life Sciences to the next level,” said Mr. Howard, who founded the company in 1991. “He has the vision, leadership and focus needed to pilot a multinational company to the forefront of its industry.”
A retired U.S. naval commander, Price was named president of RBC Life Sciences in December 2007. He will retain the position of president after being promoted to CEO January 1. Prior to joining the company, he served as a senior executive for two major companies that market nutritional supplements domestically and internationally. Price also led a successful management consulting company and spent 17 years as a senior officer of pharmaceutical giant Eli Lilly.
“It’s an exciting time for RBC Life Sciences,” said Price, a triathlon athlete who practices the healthy nutrition and exercise promoted by the company. “We’re redoubling our efforts to grow our North American market while undertaking aggressive international expansion. We have a healthy balance sheet driven by sales of nutritional supplements and medical device products that are backed by science and are receiving increasing accolades within their industries.”
The company’s medical devices brand, MPM Medical Inc., is growing strongly. Sales of MPM’s evidence-based prescription and non-prescription wound care and pain management products increased 42 percent during the third quarter of 2008 compared to the same period last year. The Kroger Co. began carrying some of MPM’s products in its 1,900 pharmacies nationwide in March 2008. The public may purchase MPM products directly from the company’s Web site: www.mpmmedicalinc.com.
In his previous company, Carrington Labs, Mr. Howard assembled the team of scientists responsible for discovering the most-active compound responsible for the renowned health-giving benefits of the aloe vera plant. He leaves a 50-year legacy that has touched lives around the world. Some of his many career milestones include serving as founding president of the hospital now named Baylor Medical Center at Irving, creating the nation’s first network of clinical laboratories in the 1960s and founding RBC Life Sciences, a company whose products are receiving worldwide critical acclaim.
“It’s been a humbling journey,” said Mr. Howard. “An impetus for much of what I’ve tried to accomplish in my personal and business life follows the adage: ‘It doesn’t have to be this way.’ You don’t have to settle for status quo when it comes to helping others.”
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company’s Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company’s management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company’s filings with the Securities and Exchange Commission.
CONTACT: Alan Van Zelfden, +1-972-893-4050,
alan.vanzelfden@rbclifesciences.com, or Ann Billings, +1-972-893-4000,
ann.billings@rbclifesciences.com, both of RBC Life Sciences
Web site: http://www.mpmmedicalinc.com/
http://www.rbclifesciences.com/
